Immatics develops PRAME-targeted cancer treatments, including cell therapies and bispecific drugs, for patients with advanced cancers. IMTX reports earnings on Tue, Nov 17, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 14 | Stifel | Initiated | Buy | |
| May 19 | Chardan Capital | Maintained | Buy |
Seasonality
How IMTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in IMTX in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMTX is in one of them and how their past IMTX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IMTX in an article yet. Here's the latest on the wider market.
About Immatics N.V.
Immatics is a biopharmaceutical company based in Tubingen, Germany, that develops cancer treatments aimed at PRAME, a protein found on the surface of many tumor cells. Its main products are T cell receptor therapies in two forms. Its cell therapies are made individually for each patient, while its bispecific drugs are made in advance and distributed through standard pharmaceutical supply channels. The treatments are intended for patients with advanced cancers, such as melanoma, and are given through specialized hospitals and medical centers.
- Headquarters
- Tubingen, Germany